+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are conducting an observational study to collect and store tissue and blood samples from patients diagnosed with various types of cancer, including hematopoietic and lymphatic system neoplasms and malignant solid tumors. The aim is to create preclinical models that help scientists better understand cancer and test new treatments. This research is sponsored by the National Cancer Institute LAO and involves patients being treated or evaluated for cancer at participating sites. During the study, tissue and blood samples are collected during clinical procedures that patients are already undergoing as part of their cancer care. These samples are preserved through methods such as xenograft models, where tissue is transplanted into another species, or in vitro cell cultures for future laboratory analysis. There are no experimental treatments given instead, the study focuses on obtaining and storing biological materials. Participants will be involved by allowing collection of their tissue and blood samples during their routine medical procedures. The research team will monitor the procurement of these specimens for up to five years. No additional treatments are administered as part of the study. The primary outcome measured is the successful collection and storage of tissue and blood samples to support future cancer research and model development.

Age: 2Months +All Genders
140 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating whether a data coaching process called Out of School Time Coach OST-Coach can increase physical activity among children, improve their perceived motor skills, and encourage staff to promote physical activity more effectively. This randomized controlled trial aims to see if targeted data coaching helps children in after-school programs engage in more physical activity and enhances staff practices compared to standard methods. The study involves two groups one receiving the OST-Coach intervention and the other continuing standard practice. The OST-Coach intervention includes four data coaching sessions throughout the academic year following the steps of investigate, design, practice, and reflect. During these sessions, site leaders receive customized data reports and set goals to improve child physical activity, motor competence, and staff behavior. The control group only receives data reports without coaching. Participants are children enrolled in elementary-level after-school programs. Researchers will measure child physical activity through observation and surveys about motor skills, while staff behavior will be observed and surveyed to assess physical activity promotion. Feedback is provided four times during the year. The main outcome is child physical activity tracked over one year, with staff behaviors and perceived motor competence also evaluated. The study runs from September 2025 to July 2026 with no masking.

Age: 5Years - 11YearsAll GendersPhase Not Applicable
1 location
L

Actively Recruiting

Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.

Age: 18Years +All GendersPhase 2Phase 3
1229 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are studying muscle weakness and loss during short periods of arm immobilization in midlife women aged 40 to 65. The trial aims to understand how the nervous system changes cause weakness when a wrist is immobilized and whether exercising the opposite arm can help maintain strength, muscle size, and nervous system function in the immobilized arm. This study uses a randomized controlled design with participants divided by menopausal status. Participants will wear a hard wrist cast on their non-dominant arm for 7 days to induce muscle weakness. One group will perform resistance training with the opposite arm during immobilization, while the control group will remain inactive. After cast removal, all participants will undergo a 2-week rehabilitation program with progressive resistance exercises to restore wrist strength and function in the previously immobilized arm. Throughout the study, participants will attend visits for strength testing and nervous system assessments, including non-invasive measures such as magnetic brain stimulation, muscle recordings, and imaging. Researchers will measure handgrip strength, wrist extension and flexion strength, muscle size via CT imaging, and various nervous system activity markers before immobilization, immediately after, and after rehabilitation. The total study duration is approximately 3 weeks, including immobilization and recovery phases.

Age: 40Years - 65YearsFEMALEPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are studying adults with depression and anxiety to understand how nature-based physical activity affects these conditions. The study involves licensed therapists and their clients and aims to see how a 10-week outdoor walk-and-talk therapy program might change depression and anxiety symptoms. The project also looks at how participating in nature-based activities impacts physical activity levels and mental health. Ten therapists will be trained to carry out the study, then each will recruit six adult clients diagnosed with depression or anxiety. Clients will be randomly placed in either the intervention group, which will participate in weekly outdoor walk-and-talk therapy sessions and set goals for more outdoor activity, or the control group, which will receive educational materials and access to the intervention after 10 weeks. Both groups will use a Fitbit and the NatureDose app to track activity and time spent in nature. Participants will complete surveys about their depression and anxiety symptoms before and after the 10-week program. Therapists will keep weekly logs of therapy sessions, and clients will log their nature-based activities. At the end, clients will fill out satisfaction surveys, and therapists will be interviewed. The study measures include participation in therapy, therapist support, acceptability of the program, physical activity, time spent in nature, and self-efficacy for physical activity and nature engagement.

Age: 18Years - 65YearsAll GendersPhase 2
1 location
P

Actively Recruiting

Researchers are evaluating a phase III trial comparing shorter chemotherapy-immunotherapy without anthracycline drugs to the usual chemo-immunotherapy for treating early-stage triple negative breast cancer TNBC. This study aims to see if the shorter treatment works as well as the usual anthracycline-containing treatment. The trial also assesses patient-reported outcomes like fatigue and physical function, as well as safety and survival measures. It involves participants with specific stages of TNBC and includes detailed evaluations of tumor response and immune markers. Participants are randomly assigned to one of two treatment groups. One group receives paclitaxel, carboplatin, and pembrolizumab followed by doxorubicin, cyclophosphamide, and pembrolizumab, then surgery, with possible pembrolizumab after surgery. The other group receives docetaxel, carboplatin, and pembrolizumab prior to surgery, with possible pembrolizumab after surgery. Blood samples may be collected throughout the trial for research purposes. During the study, participants undergo surgery after chemotherapy-immunotherapy. They are followed every six months for two years, then annually up to five years. Assessments include breast cancer event-free survival, pathological response, distant relapse-free survival, overall survival, adverse events, and patient-reported fatigue and physical function. Quality of life and other patient-reported symptoms are also evaluated. Specimens are banked for future research. The total participation may last up to five years from registration.

Age: 18Years +All GendersPhase 3
963 locations
A

Actively Recruiting

Healthy Volunteer

This research investigates how a mobile app called Flourish may affect the well-being of students. It aims to understand whether access to the Flourish app increases positive feelings, reduces loneliness, and improves a sense of belonging. The study compares three groups to evaluate if the app alone or combined with a human buddy leads to better well-being outcomes over existing school resources. Participants are randomly assigned to one of three groups a waitlist control group continuing with regular school resources and given external mental health information a group using the Flourish app twice weekly for six weeks and a group using the app twice weekly while also engaging with a buddy. The Flourish app includes a science-based digital toolkit and an AI chatbot designed to support student well-being. During the six-week period, participants complete four brief online surveys measuring mood, loneliness, social support, mindfulness, resilience, life satisfaction, and relationships with the Flourish buddy if applicable. These assessments occur at the start, throughout, and at the end of the study. Researchers monitor well-being changes and enrollment intentions to understand how the app and social support influence student flourishing.

Age: 18Years +All GendersPhase Not Applicable
11 locations
E

Actively Recruiting

Researchers are evaluating the addition of pembrolizumab, a type of immunotherapy, to standard chemotherapy for patients with stage IIA, IIB, IIIA, or IIIB non-small cell lung cancer NSCLC that has been completely removed by surgery. This phase III trial aims to compare disease-free survival and overall survival between different treatment approaches, including chemotherapy alone and chemotherapy combined with pembrolizumab. The study also investigates side effects, drug discontinuation rates, quality of life, and specific biomarkers such as PD-L1 expression and tumor mutational burden. Participants are randomly assigned to one of two treatment groups. Both groups initially receive one of four chemotherapy regimens every 21 days for four cycles, chosen by their doctor. In one group, pembrolizumab is given after chemotherapy as an intravenous infusion every 21 days for up to 17 cycles or every 6 weeks for up to 16 cycles. In the other group, pembrolizumab is given together with chemotherapy during the initial cycles and then continued as monotherapy. Patients undergo various scans and blood tests throughout the study, including echocardiograms, MRIs, CT scans, and blood sample collections. During the trial, participants are closely monitored for disease status and side effects. Follow-up visits occur six weeks after treatment, then every three months for two years, every six months for years two to four, and annually for up to ten years after randomization. Quality of life questionnaires and symptom assessments are also completed. The main measure of success is disease-free survival, tracked for up to five years after enrollment. Safety and overall survival are reviewed for up to ten years to ensure long-term monitoring.

Age: 18Years +All GendersPhase 3
1151 locations
E

Actively Recruiting

This trial studies patients with rare genitourinary tumors that have spread from their original site to other parts of the body. It evaluates the combination of cabozantinib with two immunotherapy drugs, nivolumab and ipilimumab, to see how well this approach works. The study focuses on patients who have few or no treatment options, aiming to assess response rates and survival outcomes. Participants receive cabozantinib orally daily on specific days during treatment cycles, alongside nivolumab and ipilimumab given intravenously at the start of initial cycles. After four cycles, nivolumab is continued alone every 28 days. Treatment continues for up to two years unless the disease progresses or side effects are unacceptable. Imaging tests like CT, MRI, bone scans, and PETCT scans are performed throughout the study to monitor disease and treatment effects. During the trial, patients undergo various assessments including echocardiography, blood and urine tests, and scans to track tumor response and safety. After completing treatment, participants are followed every two months for up to five years to observe long-term outcomes. The main focus is on objective tumor response, with additional monitoring of survival and side effects over time.

Age: 18Years +All GendersPhase 2
582 locations
E

Actively Recruiting

Researchers are evaluating a combination therapy for adults with newly diagnosed multiple myeloma not intended for early autologous transplantation. This phase III trial compares a four-drug regimen including daratumumab, bortezomib, lenalidomide, and dexamethasone to a three-drug regimen of daratumumab, lenalidomide, and dexamethasone. The study aims to determine if adding bortezomib improves overall survival and progression-free survival in patients with different minimal residual disease statuses, while also assessing side effects and patient-reported outcomes. All participants first receive standard induction therapy with daratumumab given subcutaneously on specific days, lenalidomide orally daily for 21 days, and dexamethasone orally on certain days, repeated every 28 days for 9 cycles. After induction, patients are randomly assigned to one of two consolidation and maintenance arms one adding bortezomib to the consolidation phase followed by maintenance with daratumumab and lenalidomide, and the other continuing with daratumumab, lenalidomide, and dexamethasone for consolidation and maintenance. Treatments continue in cycles of 28 days unless disease progresses or unacceptable side effects occur. During the study, participants undergo various assessments including bone marrow aspirates, blood tests, imaging with PETCT scans, and patient-reported quality of life evaluations. Researchers monitor overall survival, progression-free survival, response rates, adverse events, and neuropathy symptoms over periods up to 15 years. Follow-up visits occur every 3 months for up to 2 years, then less frequently, ensuring long-term monitoring of treatment effects and safety.

Age: 18Years +All GendersPhase 3
647 locations

1-10 of 12

1